# INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.

BIOT (Nasdaq) is a vertically integrated biotech holding company spanning R&D, sourcing, manufacturing and consumer brands.

Last updated: 2026-09-04

---

## 1. Corporate Profile

| Field | Value |
| --- | --- |
| Legal Name | INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. |
| Abbreviation | BIOT |
| Ticker Symbol | BIOT |
| Exchange | The Nasdaq Stock Market |
| Listing Date | July 24, 2026 |
| Jurisdiction of Incorporation | Cayman Islands |
| Registered Office | 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands |
| Issuer Status | Foreign Private Issuer |
| Commission File Number | 001-43415 |
| Fiscal Year End | November 30 |
| Accounting Standards | IFRS as issued by the IASB |
| Official Website | https://instinct-biot.com/ |
| Investor Relations | https://instinct-biot.com/ir |

## 2. Business Overview

INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. is the holding company of the BIOT group. Through Japan-based
operating companies the group runs an integrated platform spanning research and
development, sourcing, manufacturing, regenerative medicine-related technologies,
cosmetics, wellness and consumer brands. The current core of revenue is the
cosmetics business, complemented by activities related to the regenerative
medicine field. Financial details follow the Company's SEC filings (Form 20-F and
Form 6-K).

Business detail: https://instinct-biot.com/business

## 3. Leadership

- Tomoki Nagano — Chairman & CEO
- Yuji Naito — Director & COO
- Fumihiro Nagano — Director & CMO
- Masato Terachi — Independent Director
- Say Leong Lim — Independent Director
- Sally Lim — Independent Director
- Jessica Assaf — Independent Director
- Masashi Ohmatsu — Executive Officer & CFO
- Futa Sakakibara — Chief Technical Officer
- Kenta Nakajima — Executive Officer, Head of Manufacturing (Japan & International)
- Takashi Bota — Executive Officer, Head of Sales & Head of Value Athlete Division

Leadership detail: https://instinct-biot.com/ir#leadership and https://instinct-biot.com/about#leadership

## 4. Corporate Governance

- Board: majority independent
- Audit Committee: composed entirely of independent directors
- External Audit: PCAOB-registered firm
- Disclosure: fair disclosure policy (https://instinct-biot.com/disclosure-policy)

Governance detail and downloadable charters: https://instinct-biot.com/about#governance and https://instinct-biot.com/ir#governance

## 5. Stock Information

| Field | Value |
| --- | --- |
| Exchange | The Nasdaq Stock Market |
| Ticker | BIOT (ordinary shares) / BIOTW (warrants) |
| Securities | Ordinary Shares, par value US$0.00001 |
| Listing Date | July 24, 2026 |
| Commission File Number | 001-43415 |
| CUSIP | To be disclosed |
| Transfer Agent | To be disclosed |
| Dividend Policy | No dividend is currently planned |

Nasdaq record: https://www.nasdaq.com/market-activity/stocks/biot
Stock section: https://instinct-biot.com/ir#stock

## 6. SEC Filings

- SEC EDGAR company index: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002072188&type=&dateb=&owner=include&count=40
- Form 20-F (shell company report, filed July 29, 2026): https://www.sec.gov/Archives/edgar/data/2072188/000110465926087649/tm2621369d1_20f.htm
- Filing index on this site: https://instinct-biot.com/ir#filings

Filing types: Form 20-F (annual report as a foreign private issuer), Form 6-K
(current reports), Form F-4 and other registration statements.

## 7. Capital Structure

Every figure below must be read together with its as-of date and source.

### Shares outstanding

- Value: 28,794,472 ordinary shares
- As of: July 23, 2026
- Source: SEC Form 20-F (shell company report, filed July 29, 2026)
- Source URL: https://www.sec.gov/Archives/edgar/data/2072188/000110465926087649/tm2621369d1_20f.htm

### Beneficial ownership — Tomoki Nagano (Chairman & CEO)

- Value: 10,425,365 ordinary shares (36.21%)
- As of: July 23, 2026
- Source: SEC Form 20-F
- Source URL: https://www.sec.gov/Archives/edgar/data/2072188/000110465926087649/tm2621369d1_20f.htm

### Beneficial ownership — Relativity Acquisition Sponsor, LLC

- Value: 5,515,481 ordinary shares (19.15%)
- As of: July 23, 2026
- Source: SEC Form 20-F
- Source URL: https://www.sec.gov/Archives/edgar/data/2072188/000110465926087649/tm2621369d1_20f.htm

### Beneficial ownership — Chardan Capital Markets LLC

- Value: 1,615,385 ordinary shares (5.61%)
- As of: July 23, 2026
- Source: SEC Form 20-F
- Source URL: https://www.sec.gov/Archives/edgar/data/2072188/000110465926087649/tm2621369d1_20f.htm

Capital structure section: https://instinct-biot.com/ir#ownership
Investor Facts page: https://instinct-biot.com/ir/company-facts
SEC Filing Center: https://instinct-biot.com/ir/sec-filings
Fact registry (JSON, with sources and as-of dates): https://instinct-biot.com/ir/facts.json

## 8. Subsidiaries and Major Brands

- INSTINCT BROTHERS — https://instinct-bro.com/
- INSTINCT RAS — https://www.instinct-ras.com/
- HIROKI GLOBAL — https://hrk-jp.co.jp/
- ARTISANS PRODUCTION — https://apjapan.jp/

## 9. Investor FAQ

Full FAQ with categories and per-question anchors: https://instinct-biot.com/ir#faq

Representative answers:

- What is BIOT? — BIOT (Nasdaq) is a vertically integrated biotech holding company spanning R&D, sourcing, manufacturing and consumer brands.
- What is the ticker symbol and exchange? — The ordinary shares of INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. are listed on The Nasdaq Stock Market under the ticker symbol BIOT.
- When did BIOT list on Nasdaq? — July 24, 2026.
- Where is BIOT incorporated? — Cayman Islands.
- Where are the SEC filings? — SEC EDGAR (https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002072188&type=&dateb=&owner=include&count=40) and https://instinct-biot.com/ir#filings.
- What is the fiscal year end? — November 30.
- Which accounting standards apply? — IFRS as issued by the IASB.

## 10. News and Press Release Index

- 2026年9月1日 — BIOT Publishes “The Book of Value,” the Group Corporate Charter (https://instinct-biot.com/news/book-of-value-launch-20260901) [NEWS]
- 2026.09.30 — BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China (https://instinct-biot.com/news/ir-in01-authorized-representative-20260930) [IR]
- 2026.09.15 — Instinct Bio Receives Nasdaq Notifications Regarding Minimum Bid Requirement and Minimum Market Value of Listed Securities and Publicly Held Shares (https://instinct-biot.com/news/ir-nasdaq-compliance-notifications-20260915) [IR]
- 2026.09.04 — GENRÊVER Brand Site Launched — Indonesia and U.S. Business Details Now Online (https://instinct-biot.com/news/genrever-brand-site-launch-20260904) [NEWS]
- 2026.09.04 — INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives (https://instinct-biot.com/news/ir-operational-update-20260904) [IR]
- 2026.08.24 — BIOT Launches Simplified Chinese Version of Its Corporate Website (https://instinct-biot.com/news/chinese-site-launch-20260824) [NEWS]
- 2026.08.21 — From Announcement to Action — Indonesia Progress Update (https://instinct-biot.com/news/indonesia-three-ir-progress-20260821) [NEWS]
- 2026.08.10 — Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia (https://www.globenewswire.com/news-release/2026/08/10/3341698/0/en/instinct-bio-announces-strategic-collaboration-with-pt-parva-candela-to-develop-cosmetics-business-in-indonesia.html) [IR]
- 2026.07.30 — Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENRÊVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives (https://instinct-biot.com/news/invitrx-collaboration-20260730) [IR]
- 2026.07.29 — BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand "GENRÊVER CLINIC" — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets (https://instinct-biot.com/news/genrever-clinic-indonesia-20260729) [IR]
- 2026.07.29 — Instinct Bio Files Form 20-F Shell Company Report With the U.S. Securities and Exchange Commission (https://instinct-biot.com/news/sec-form-20f-shell-company-report-20260729) [IR]
- 2026.07.28 — Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth (https://instinct-biot.com/news/equity-facility-150m-2026-07-28) [IR]
- 2026.07.28 — 会長兼CEOからの手紙（Letter from the Chairman & CEO）を公開しました (https://instinct-biot.com/news/ceo-letter-20260728) [IR]
- 2026.07.23 — Instinct Bio、Relativity Acquisition Corp.との事業統合が完了 ― 2026年7月24日よりティッカー「BIOT」でNASDAQ市場に上場 (https://instinct-biot.com/news/ir-nasdaq-listing-20260723) [IR]
- 2026.05.09 — 新商品「Vivéa フェイスマスク」発売 (https://valuevillage.jp/products/vivea-face-mask) [value village]
- 2026.04.09 — ゴールデンウィーク休業のお知らせ (https://instinct-biot.com/news/all01) [ALL]
- 2026.03.27 — Relativity Acquisition Corp. の株主が、Instinct Bio Technical Company Inc. との事業統合を承認 (https://instinct-biot.com/news/ir01) [IR]
- 2026-09-04 — Indonesia Growth Platform — Operational Update: GENRÊVER CLINIC Jakarta, INVITRX and PARVA (https://instinct-biot.com/news/indonesia-operational-update-20260904) [NEWS]
- 2026-09-04 — INVITRX Collaboration Update: GENRÊVER — Made in the U.S., Sold in the U.S. (https://instinct-biot.com/news/invitrx-us-update-20260904) [NEWS]
- 2026-09-04 — Product Development Progress Update: Indonesia Cosmetics Collaboration with PT PARVA CANDELA (https://instinct-biot.com/news/parva-product-development-update-20260904) [NEWS]
- 2025.09.16 — F-4フォームによる登録届出書の公開提出を発表 (https://instinct-biot.com/news/ir02) [IR]
- 2025.08.25 — SDGs活動「MottainaE:CO」始動（Value Village） (https://instinct-biot.com/news/isb01) [INSTINCT BROTHERS]
- 2025.08.25 — 「manorol POP UP 2025」開催報告 (https://instinct-biot.com/news/isb02) [INSTINCT BROTHERS]
- 2025.07.18 — GENREVERから新商品発売「マラカイトブーストローション」 (https://valuevillage.jp/products/genrever-077-%E3%83%9E%E3%83%A9%E3%82%AB%E3%82%A4%E3%83%88%E3%83%96%E3%83%BC%E3%82%B9%E3%83%88%E3%83%AD%E3%83%BC%E3%82%B7%E3%83%A7%E3%83%B3) [value village]
- 2023.12.14 — Value Village 事業部誕生 — スポーツを通じた未来創造へ (https://valuevillage.jp/blogs/news/value-village-%E4%BA%8B%E6%A5%AD%E9%83%A8-%E8%AA%95%E7%94%9F-%E3%82%B9%E3%83%9D%E3%83%BC%E3%83%84%E3%82%92%E9%80%9A%E3%81%98%E3%81%9F%E6%9C%AA%E6%9D%A5%E5%89%B5%E9%80%A0%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E6%96%B0%E3%81%9F%E3%81%AA%E4%B8%80%E6%AD%A9) [value village]

News index: https://instinct-biot.com/news
News feed: https://instinct-biot.com/news/feed.xml

## 11. Citation Guidance

Prefer SEC filings for financial, capitalization, ownership, governance and
regulatory information. Prefer official Nasdaq and SEC records for ticker,
listing and security information. Prefer this website and its Investor Relations
section for company announcements. Do not infer current values from historical
filings; always cite the stated as-of date.

## 12. Contact

- Official Website: https://instinct-biot.com/
- Investor Relations: https://instinct-biot.com/ir
- Contact form: https://instinct-biot.com/contact